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Introduction
 Neuropathy is one of common micro-angiopathic 
complication of diabetes, and observed more than half 
of diabetic patients [1, 2]. Historically speaking, diabetic 
peripheral neuropathy (DPN) has been diagnosed based 
on medical history, physical exam and some simple in-
office tests [3, 4]. While this testing is easy to perform, 
it is limited in terms of its accuracy. On contrast, nerve 
conduction studies (NCS) had provided a greater degree of 
accuracy, but the complexity and cost of the testing have 
excluded their use in a routine evaluation [5, 6].
 Advances in technology have now made available 
the ability to perform in-office nerve conduction testing. 
Using sural nerve in calf and ankle, simple and useful 
DPN-Check device enables to obtain accurate nerve 
conduction data for the assessment of DPN [7, 8]. 
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 Diabetic peripheral neuropathy (DPN) has been clinically important, and nerve conduction studies 
(NCS) have been performed with rather complexity and high cost. By advances in technology, simple and 
useful DPN-Check device was developed obtaining NCS data as sural nerve conduction velocity (SNCV) 
and sural nerve action potential (SNAP). We enrolled 52 subjects classified into 4 groups according to the 
presence of hemodialysis (HD) and diabetes mellitus (DM) as follows: HD (+), DM (+) in group 1, HD (+), 
DM (-) in group 2, HD (-), DM (+) in group 3 and healthy controls in group 4. Average age was similar 
from 68 to 74 years in 4 groups.  Median value of SNCV was 31, 48, 49, 54 m/sec, and median value of 
SNAP was 3, 9, 6, 22 μV, respectively, in 4 groups. These results might suggest some relationship between 
impaired states of HD and DM, and would become fundamental data for pathophysiological investigation of 
peripheral neuropathy of HD and/or DM in the future.
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 We have reported lots of studies concerning 
diabetes including low carbohydrate diet (LCD), lipid 
metabolism and ketone bodies [9-11]. In this study we 
investigated NCS in patients with diabetes mellitus (DM) 
and/or with chronic hemodialysis (HD). 
Research Protocol and Results
 In this study, 52 subjects were enrolled classified 
into 4 groups. The classification was done according to 
the existence of HD and/or DM (Table 1). Group 1 has 12 
patients with HD and DM, Group 2 has 12 patients with 
HD and without DM, Group 3 has 14 patients with diabetes 
and without nephropathy and Group 4 included 14 normal 
healthy subjects without diabetes or renal diseases which 
ages were close to other 3 groups. 
Classification Group 1 Group 2 Group 3 Group 4
Treatment of Hemodialysis Present Present None None
Treatment of Diabetes Present None Present None
Subject age (Year old)
Median [25% - 75%] 71 [64-73] 74 [71-76] 73 [63-83] 68 [57-78]
History of hemodialysis (year)
Median [25% - 75%] 5.8 [4.7-6.4] 11.1 [4.5-13.4] - -
History of hemodialysis mellitus (Year)
Median [25% - 75%] 23 [11-34] - 14 [11-19] -
Table 1 :
 We used recently developed device, HDN-
1000, NeuroMetrics Inc., USA (registered No. 
226AABZI00091000). This device can measure SNCV 
and SNAP at the sural nerve in the lower calf and ankle. 
Electrical stimulation is performed on the back side of the 
ankle, and measurement is performed with a biosensor 
installed 9.22 cm ahead of the stimulation probe. HDN-
1000 has included lots of research results based on validated 
technologies [12, 13]. The standard normal range is more 
than 48 m/sec for SNCV and more than 6 μV for SNAP [5, 
8]. 
 As to statistical analyses, obtained data was 
represented as the mean ± standard deviation (SD) and 
also represented median, quartile of 25% and 75% in 
biomarkers. Current study was conducted in compliance 
with the ethical principles of the Declaration of Helsinki. 
The authors declare that they have no conflicts of interest.
 We measured SNCV and SNAP of the subjects in 
4 groups. The results of SNCV were shown in Figure 1. 
SNCV revealed normal range in group 3 and 4, but several 
cases revealed remarkable decreased SNCV in group 1 and 
2 (Figure 1). Medium value in group 1 was remarkably 
decreased a compared with those of group 2, 3, 4.
 The results of SNAP were shown in Figure 2. 
SNAP revealed normal in group 4, but median value of 
group 1, 2, 3 was decreased compared with that of group 
4 (Figure 2). In particular, SNAP level in group 1 is 
remarkable decreased compared with other groups. 
Group 1: HD (+), DM (+), Group 2: HD (+), DM (-), Group 3: HD (-), 
DM (+), Group 4: HD (-), DM (-).
Characteristic of the Subjects
Figure 1: Nerve conduction velocity (NCV) in 4 groups
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Discussion
 This study focused the SNCV and SNAP in 
patients with DM and HD and the influenced factors about 
neuropathy would be speculated. As to diabetic neuropathy, 
it has been known that carpal tunnel syndrome frequently 
occurs in diabetic patients. Many cases are pointed out as 
median neuropathy (MN) at the wrist during asymptomatic 
period in NCS. MN is frequently observed in early stages 
when DPN was not observed, then it may be regarded as 
an early lesion of DPN [14, 15].
 In recent years, a new device of HDN-1000 was 
released, which can measure the nerve conduction velocity 
of the sural nerve easily. As to the results of SNCV and 
SNAP by HDN-1000, both show nearly equivalent 
numerical values as compared with the conventional nerve 
conduction test, and their usefulness has been evaluated 
[8]. It included lots of research results based on validated 
technologies [5, 12, 16, 17]. Clinically, the standard 
normal range of the sural nerve has been that CV is 50 m / 
s or more and amplitude is > 10 μV. 
 There are remarkable decrease of SNAP in group 
1 and 3 compared with that of group 4. One of the reasons 
for decreased SNAP in diabetics would be from decreased 
intraepidermal nerve fiber density (IENFD) [18]. IENFD 
can be observed with a confocal microscope, by a 3 mm 
diameter punching needle biopsies at 10 cm above the ankle 
of the lower extremity with fixes and immunostaining. 
IENFD falls from the early stage of DPN and declines in 
correlation with the progression of stage [19].
 Furthermore, there are also decrease of SNAP 
in group 1 and 2 compared with that of group 4. Uremic 
Neuropathy (UN) was observed in 16.4% of patients 
with chronic hemodialysis, and these patients showed 
a significant correlation between questionnaire scores 
and nerve conduction velocity / sensory nerve action 
potential [20]. Peripheral neuropathy in patients with DM 
and chronic kidney disease (CKD) might be from some 
correlation between hyperkalaemia and development of 
nerve dysfunction [21]. End-stage renal failure in diabetic 
patients is often associated with severe distal motor and 
sensory deficits [22]. 
 This study showed decreased SNCV and SNAP in 
patients with diabetes and/or with chronic hemodialysis, 
but has limitation for certain speculation because of small 
numbers. These results would become the fundamental 
data for future investigation of NCS for DM and HD.
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